Это важно.

Мы предлагаем удобный сервис для тех, кто хочет купить – продать: земельный участок, дом, квартиру, коммерческую или элитную недвижимость в Крыму. //crimearealestat.ucoz.ru/ Перепечатка материалов разрешена только при условии прямой гиперссылки //allmedicine.ucoz.com/

Поиск

Реклама

Statistics


Онлайн всего: 1
Гостей: 1
Пользователей: 0

Нас смотрят

free counters

Ссылки.

Мы предлагаем удобный сервис для тех, кто хочет купить – продать: земельный участок, дом, квартиру, коммерческую или элитную недвижимость в Крыму. //crimearealestat.ucoz.ru/

Чат

Adverse Event Reporting Timelines

  • Expedited Reporting:

    • Regulatory authorities require expedited reporting for serious and unexpected adverse events during clinical trials.

    1. Serious Adverse Events (SAEs):
      • Timeline: Must be reported to the sponsor immediately (typically within 24 hours of becoming aware of the event).
      • The sponsor is responsible for further reporting to regulatory authorities (e.g., FDA, EMA) within 7 days for life-threatening or fatal events and 15 days for other serious events.
    2. Suspected Unexpected Serious Adverse Reactions (SUSARs):
      • Timeline: Sponsors must report life-threatening or fatal SUSARs to regulatory authorities within 7 days and provide follow-up information within 8 days.
      • Non-life-threatening SUSARs should be reported within 15 days.
  • Non-Serious Adverse Events:

    • These events are generally reported in the study’s final report or during periodic safety updates rather than on an expedited basis.

    1. Non-Serious AEs:
      • Typically recorded and monitored but not subject to expedited reporting unless required by the protocol or the regulatory authority.

3. Responsibilities for Adverse Event Reporting

  1. Investigators:

    • Primary Responsibility: The investigator is responsible for identifying and documenting AEs and SAEs during the clinical trial.
    • AE Reporting: The investigator must report all SAEs immediately to the sponsor, usually within 24 hours of becoming aware of the event.
    • Follow-Up: The investigator must provide follow-up information to the sponsor to complete the AE or SAE report.
  2. Sponsors:

    • Sponsor’s Role: The sponsor is responsible for the prompt assessment of all AEs and SAEs, determining causality, and reporting SUSARs to regulatory authorities.
    • Expedited Reporting: Sponsors must submit reports of SUSARs and other reportable SAEs to regulatory agencies within the required timelines.
    • Annual Safety Reporting: Sponsors are often required to submit annual safety reports (e.g., DSUR—Development Safety Update Report) summarizing all AEs and SAEs observed during the trial.
Раскрутка сайта - регистрация в каталогах PageRank Checking Icon Яндекс цитирования